Formulation, Development & Evaluation of Valsartan Tablet

Abstract

Osmotically regulated Valsartan drug distribution was the study's major goal. BCS class I medication Valsartan treats hypertension. This system seeks zero-order Valsartan release. This study also established a mechanism to reduce dose frequency, interpatient variability, adverse effects, and patient compliance. HPMC K100M polymer and Mannitol osmotic agent were drug-compatible. FTIR spectra of the physical combination demonstrate drug-polymer compatibility. This technique was created in two steps: formulation of core tablet and coating/drilling of orifice. Coated tablets were examined for in-vitro release research and hardness, thickness, friability, weight variation, and content consistency. All formulations dispersed well. Valsartan had 99.99% drug release in 12 hours. Direct compression produced Valsartan osmotic tablets. Polymeric HPMC K100M with osmotic Mannitol. Pre-compression characteristics such bulk density, tapped density, angle of repose, hausner ratio, and carr`s index were tested. Direct compression formed valsartan osmotic tablets. Different osmogen concentrations were tested on osmotic tablets. The osmotic tablet was made by coating the core tablet containing medicine and osmogen with a semipermeable membrane to allow water penetration and drilling an aperture to release drug after adequate osmotic pressure. First, drug solubility, melting point, and IR were studied. F1, F2, F3, F4, and F5 release drug at 12 hours. The stability research formulations were tested for physical appearance, hardness, thickness, and in-vitro dissolution for three months. The formulation parameters remained steady, indicating stability.